Lymphocyte activating gene 3 protein expression in nasopharyngeal carcinoma is correlated with programmed cell death-1 and programmed cell death ligand-1, tumor-infiltrating lymphocytes

Immunotherapy has shown promising efficacy in patients with nasopharyngeal carcinoma (NPC). Lymphocyte activating 3 gene (LAG-3) represents a significant immune target, however, its relationship with NPC remains unclear. This study aimed to evaluate LAG-3 expression in NPC and its association with C...

Full description

Saved in:
Bibliographic Details
Published in:Cancer cell international 2021-08, Vol.21 (1), p.458-458, Article 458
Main Authors: Luo, Fan, Cao, Jiaxin, Lu, Feiteng, Zeng, Kangmei, Ma, Wenjuan, Huang, Yan, Zhang, Li, Zhao, Hongyun
Format: Article
Language:English
Subjects:
Antibodies
Antigens
Apoptosis
Cancer therapies
CD223 antigen
CD3
CD3 antigen
Cell death
Epstein-Barr virus
Granzyme B
GZMB
Immunohistochemistry
Immunotherapy
LAG-3
Ligands
Lymphocytes
Medical prognosis
Metastasis
Nasopharyngeal carcinoma
NPC
Patients
PD-1
PD-1 protein
PD-L1
PD-L1 protein
Primary Research
Proteins
Risk factors
Throat cancer
Tumor cells
Tumor-infiltrating lymphocytes
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Immunotherapy has shown promising efficacy in patients with nasopharyngeal carcinoma (NPC). Lymphocyte activating 3 gene (LAG-3) represents a significant immune target, however, its relationship with NPC remains unclear. This study aimed to evaluate LAG-3 expression in NPC and its association with CD3+ tumor-infiltrating lymphocytes (TILs), Granzyme B (GZMB), programmed death ligand 1 (PD-L1), and programmed death 1 (PD-1) expression. A total of 182 patients with NPC from Sun Yat-sen University Cancer Center, China, were included in this retrospective study. LAG-3 expression in 15 NPC cell lines and LAG-3, CD3+ TILs, GZMB, PD-L1 and PD-1 in clinical samples were estimated using immunohistochemistry. The Chi-square test was used to estimate the association between LAG-3, other biomarkers, and clinical characteristics. Survival analysis was performed using the Kaplan-Meier method and the Cox regression model. LAG-3 was negatively expressed in all of the 15 NPC cell lines, whereas, 147 patients with NPC (80.8%) exhibited high LAG-3 expression on TILs from tumor tissues. Male patients and those who were EBV-positive presented higher LAG-3 expression. Correlation analyses showed that LAG-3 expression was related to PD-1 expression on TILs, as well as, PD-L1 expression on tumor cells (TCs) and TILs. Both the univariate and multivariate Cox models indicated that pathological type III (P = 0.036), higher LAG-3 on TILs (P 
ISSN:1475-2867
1475-2867
DOI:10.1186/s12935-021-02162-w